Sensus Healthcare (SRTS) announced that president Michael Sardano has been appointed to the additional role of chief commercial officer. In this newly created position, Sardano will direct the company’s global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel software and related service models. These expanded responsibilities follow a recent reimbursement milestone from the Centers for Medicare & Medicaid Services, which established current procedural terminology codes specific to the use of superficial radiotherapy for non-melanoma skin cancer.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare Appoints Eric Sachetta as Director
- Sensus Healthcare: Strong Growth Potential and Financial Stability Drive Buy Rating
- Sensus Healthcare’s Earnings Call: Mixed Signals and Optimistic Outlook
- Sensus Healthcare Reports Q3 2025 Financial Results
- Sensus Healthcare reports Q3 EPS (6c), consensus (11c)v